Limited advances in therapy of glioblastoma trigger re-consideration of research policy

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Glioblastoma (GB - WHO grade IV) is the most frequent and lethal primary brain tumour with median overall survival of 7-15 months after diagnosis. As in other cancer research areas, an overwhelming amount of pre-clinical research acquisitions in the GB field have not been translated to patients' benefit, potentially due to inappropriate treatment schedules and/or trial designs in the clinical setting. The recent failure of promising anti-VEGF bevacizumab to improve GB patients' overall survival recapitulates this sense of frustration. The following measures are proposed:. 1.to change Phase II design. Bevacizumab and other drugs may have failed in Phase III just because of an inappropriate clinical treatment schedule adopted. Multiple-step Phase II clinical trials allowing more thorough definition of treatment protocols to be extensively studied in Phase III should be designed.2.to monitor standards of care by documenting survival rates of GB patients in European Cancer Units, in order to homogenize GB treatment quality to the highest possible level all over EU28.3.to introduce the therapeutic impact factor (TIF) and therapeutic (t) index bibliometric parameters, in order to orientate pre-clinical research toward more therapy-focussed activities.

Original languageEnglish
Pages (from-to)257-261
Number of pages5
JournalCritical Reviews in Oncology/Hematology
Volume96
Issue number2
DOIs
Publication statusPublished - Nov 1 2015

Fingerprint

Glioblastoma
Research
Appointments and Schedules
Therapeutics
Bibliometrics
Phase II Clinical Trials
Frustration
Survival
Standard of Care
Clinical Protocols
Brain Neoplasms
Vascular Endothelial Growth Factor A
Neoplasms
Survival Rate
Pharmaceutical Preparations

Keywords

  • Bevacizumab
  • Bibliometrics
  • Glioma
  • Treatment protocol
  • Treatment quality

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Limited advances in therapy of glioblastoma trigger re-consideration of research policy. / Frosina, Guido.

In: Critical Reviews in Oncology/Hematology, Vol. 96, No. 2, 01.11.2015, p. 257-261.

Research output: Contribution to journalArticle

@article{e6eeb078d1cc435ab1879bf6f4001741,
title = "Limited advances in therapy of glioblastoma trigger re-consideration of research policy",
abstract = "Glioblastoma (GB - WHO grade IV) is the most frequent and lethal primary brain tumour with median overall survival of 7-15 months after diagnosis. As in other cancer research areas, an overwhelming amount of pre-clinical research acquisitions in the GB field have not been translated to patients' benefit, potentially due to inappropriate treatment schedules and/or trial designs in the clinical setting. The recent failure of promising anti-VEGF bevacizumab to improve GB patients' overall survival recapitulates this sense of frustration. The following measures are proposed:. 1.to change Phase II design. Bevacizumab and other drugs may have failed in Phase III just because of an inappropriate clinical treatment schedule adopted. Multiple-step Phase II clinical trials allowing more thorough definition of treatment protocols to be extensively studied in Phase III should be designed.2.to monitor standards of care by documenting survival rates of GB patients in European Cancer Units, in order to homogenize GB treatment quality to the highest possible level all over EU28.3.to introduce the therapeutic impact factor (TIF) and therapeutic (t) index bibliometric parameters, in order to orientate pre-clinical research toward more therapy-focussed activities.",
keywords = "Bevacizumab, Bibliometrics, Glioma, Treatment protocol, Treatment quality",
author = "Guido Frosina",
year = "2015",
month = "11",
day = "1",
doi = "10.1016/j.critrevonc.2015.05.013",
language = "English",
volume = "96",
pages = "257--261",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Limited advances in therapy of glioblastoma trigger re-consideration of research policy

AU - Frosina, Guido

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Glioblastoma (GB - WHO grade IV) is the most frequent and lethal primary brain tumour with median overall survival of 7-15 months after diagnosis. As in other cancer research areas, an overwhelming amount of pre-clinical research acquisitions in the GB field have not been translated to patients' benefit, potentially due to inappropriate treatment schedules and/or trial designs in the clinical setting. The recent failure of promising anti-VEGF bevacizumab to improve GB patients' overall survival recapitulates this sense of frustration. The following measures are proposed:. 1.to change Phase II design. Bevacizumab and other drugs may have failed in Phase III just because of an inappropriate clinical treatment schedule adopted. Multiple-step Phase II clinical trials allowing more thorough definition of treatment protocols to be extensively studied in Phase III should be designed.2.to monitor standards of care by documenting survival rates of GB patients in European Cancer Units, in order to homogenize GB treatment quality to the highest possible level all over EU28.3.to introduce the therapeutic impact factor (TIF) and therapeutic (t) index bibliometric parameters, in order to orientate pre-clinical research toward more therapy-focussed activities.

AB - Glioblastoma (GB - WHO grade IV) is the most frequent and lethal primary brain tumour with median overall survival of 7-15 months after diagnosis. As in other cancer research areas, an overwhelming amount of pre-clinical research acquisitions in the GB field have not been translated to patients' benefit, potentially due to inappropriate treatment schedules and/or trial designs in the clinical setting. The recent failure of promising anti-VEGF bevacizumab to improve GB patients' overall survival recapitulates this sense of frustration. The following measures are proposed:. 1.to change Phase II design. Bevacizumab and other drugs may have failed in Phase III just because of an inappropriate clinical treatment schedule adopted. Multiple-step Phase II clinical trials allowing more thorough definition of treatment protocols to be extensively studied in Phase III should be designed.2.to monitor standards of care by documenting survival rates of GB patients in European Cancer Units, in order to homogenize GB treatment quality to the highest possible level all over EU28.3.to introduce the therapeutic impact factor (TIF) and therapeutic (t) index bibliometric parameters, in order to orientate pre-clinical research toward more therapy-focussed activities.

KW - Bevacizumab

KW - Bibliometrics

KW - Glioma

KW - Treatment protocol

KW - Treatment quality

UR - http://www.scopus.com/inward/record.url?scp=84955178929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955178929&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2015.05.013

DO - 10.1016/j.critrevonc.2015.05.013

M3 - Article

VL - 96

SP - 257

EP - 261

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 2

ER -